Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study

Tissue factor (TF), encoded by the F3 gene, is the main initiator of blood coagulation. The molecular epidemiology of the F3 gene and the relation to venous thromboembolism (VTE) remains to be determined. The aim was to determine the molecular epidemiology and the importance of F3 variants for incident VTE by analysis of the population-based MDC study (Malmö Diet and Cancer), consisting of unselected middle-aged and older individuals. The exons of F3 were analyzed in a total of 28,794 individuals from the MDC cohort, and of these, 2584 (9 %) were affected by VTE during follow‐up (1991–2018). Qualifying variants used in gene-collapsing analysis were defined as loss-of-function or non-benign (PolyPhen-2) missense variants with minor allele frequency less than 0.1 %. Exon sequencing of the F3 gene identified 61 different variants, 3′ UTR variants (n = 5), 5′ UTR variants (n = 9) synonymous (n = 10), in frame insertion (n = 1), splice region variants (n = 2), missense (n = 33) or loss-of-function variants (n = 1). No associations between common F3 gene variants and incident VTE were found. Seventeen rare variants were classified as qualifying and included in collapsing analysis (16 non-benign missense and 1 loss-of-function variants). The prevalence of F3 qualifying variants was 0.14 %. Seven individuals with F3 qualifying variants had VTE, while 34 individuals had no VTE. The adjusted VTE model was significant (hazard ratio = 2.1 [95 % confidence interval, 1.02–4.48], P-value = 0.045). Qualifying F3 gene variants are very rare, indicating a constrained gene. Rare but not common variation in the F3 gene may be involved in VTE. • Tissue factor, encoded by the F3 gene, is the main initiator of blood coagulation. • The genetic variation of the F3 gene and risk of venous thromboembolism was studied. • Common F3 gene variants were not associated with venous thromboembolism. • Rare qualifying F3 variants were associated with venous thromboembolism.

Authors

Institutions

Publication Details

Journal
Thrombosis Update
Published
2024-09-28
DOI
https://doi.org/10.1016/j.tru.2024.100190
Citations
2
Primary Topic
Blood Coagulation and Thrombosis Mechanisms
Type
article
Field-Weighted Citation Impact
0.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study

Gunnar Engström, Aris Baras, Christina Lind‐Halldén, Luca A. Lotta et al.
2 citations
Thrombosis Update
Blood Coagulation and Thrombosis Mechanisms
0.91
article

Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study

Gunnar Engström, Aris Baras, Christina Lind‐Halldén, Luca A. Lotta, Eric Manderstedt, Olle Melander, Johan Elf, Peter J. Svensson, Christer Halldén, Bengt Zöller
article en
2 citations

Abstract

Tissue factor (TF), encoded by the F3 gene, is the main initiator of blood coagulation. The molecular epidemiology of the F3 gene and the relation to venous thromboembolism (VTE) remains to be determined. The aim was to determine the molecular epidemiology and the importance of F3 variants for incident VTE by analysis of the population-based MDC study (Malmö Diet and Cancer), consisting of unselected middle-aged and older individuals. The exons of F3 were analyzed in a total of 28,794 individuals from the MDC cohort, and of these, 2584 (9 %) were affected by VTE during follow‐up (1991–2018). Qualifying variants used in gene-collapsing analysis were defined as loss-of-function or non-benign (PolyPhen-2) missense variants with minor allele frequency less than 0.1 %. Exon sequencing of the F3 gene identified 61 different variants, 3′ UTR variants (n = 5), 5′ UTR variants (n = 9) synonymous (n = 10), in frame insertion (n = 1), splice region variants (n = 2), missense (n = 33) or loss-of-function variants (n = 1). No associations between common F3 gene variants and incident VTE were found. Seventeen rare variants were classified as qualifying and included in collapsing analysis (16 non-benign missense and 1 loss-of-function variants). The prevalence of F3 qualifying variants was 0.14 %. Seven individuals with F3 qualifying variants had VTE, while 34 individuals had no VTE. The adjusted VTE model was significant (hazard ratio = 2.1 [95 % confidence interval, 1.02–4.48], P-value = 0.045). Qualifying F3 gene variants are very rare, indicating a constrained gene. Rare but not common variation in the F3 gene may be involved in VTE. • Tissue factor, encoded by the F3 gene, is the main initiator of blood coagulation. • The genetic variation of the F3 gene and risk of venous thromboembolism was studied. • Common F3 gene variants were not associated with venous thromboembolism. • Rare qualifying F3 variants were associated with venous thromboembolism.

Thrombosis UpdateVol. 17
Regeneron (United States) (US), Lund University (SE), Kristianstad University (SE), Skåne University Hospital (SE)
Vetenskapsrådet
Openalex Percentile: Top 23%
Blood Coagulation and Thrombosis Mechanisms
0.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.